Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan
Authors:
- 1 February 2017
- journal article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 15 (1) , 122-128
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinibMedical Oncology, 2015
- What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?Cancer Treatment Reviews, 2013
- Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS TrialJapanese Journal of Clinical Oncology, 2013
- Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: Optimizing patient benefitCancer Treatment Reviews, 2012
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 2011
- ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic DiseaseEuropean Urology, 2011
- A Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma: Insights into the Treatment, Efficacy and SafetyJapanese Journal of Clinical Oncology, 2009
- Axitinib—a selective inhibitor of the vascular endothelial growth factor (VEGF) receptorTargeted Oncology, 2009
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3Clinical Cancer Research, 2008
- Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2002